To compare the efficacy and safety of combination of moderate dose rosuvastatin with fenofibrate with high dose rosuvastatin in patients of coronary artery disease with mixed dyslipidemia and high risk patients. Randomized controlled trial. - Mixed Dyslipidemia

INDIRA GANDHI MEDICAL COLLEGE0 个研究点目标入组 165 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Age: 18 - 70 years.
•2. Patients with symptomatic stable CAD with mixed dyslipidemia (LDL-C level >100mg/dL & TG of >150mg/dL).
•3. Willing to give informed consent for the study.

•1. Lipid levels below target goals off lipid lowering agent.
•2. History of pancreatitis or cholelithiasis that has not been treated with cholecystectomy.
•3. Patient on Hormonal Replacement Therapy or oral contraceptive pills.
•4. Patient with Hepatic disease, renal disease.
•5. Patients scheduled for CABG/PCI
•6. H/O PCI/CABG within previous 3 months
•7. Pregnant or lactating female.
•8. H/O MI for less than 3 month.
•9. Patient with the history of hypersensitivity for Rosuvastatin and Fenofibrate.
•10. Type 1 diabetes mellitus or H/O Diabetic Ketoacidosis.
•11. Uncontrolled type 2 diabetes mellitus defined as HbA1c >=8.5%.
•12. History of diagnosed hereditary or acquired myopathy.
•13. Unwilling or unable to give informed consent for the study.

发起方